Navigation Links
ATS Medical Announces Record Quarterly Revenue and Gross Profit

First Quarter 2008 Revenue Increases 37.5% to $14.8 Million

Gross Profit Margin at 60.3% Sets Quarterly Record

Company Raises Revenue Guidance

MINNEAPOLIS, May 5 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported financial results for the first quarter ended March 29, 2008. Revenue for the quarter was $14.8 million, up 37.5% from $10.8 million reported in the first quarter of 2007.


Revenue growth was strong across all regions with domestic and international revenue increasing 36.2% and 38.3%, respectively. Contributing to the strong first quarter revenue growth was a 160.5% increase in revenues from the Company's ATS CryoMaze(TM) cryoablation products for the treatment of cardiac arrhythmias. Revenue from this product line rose to $3.8 million. Revenue from the Company's heart valve therapy products, consisting of mechanical valves, tissue valves and repair products, was up 18.8% on a year-over-year basis to $10.7 million. The growth reflected a 17.4% increase in mechanical valve revenue and a 70.4% increase in valve repair revenue. Revenue from products and services other than the Company's mechanical valves represented 34% of total revenue during the first quarter of 2008 compared with 23% in the first quarter of 2007.

Gross profit margin for the first quarter of 2008 set another quarterly record of 60.3% compared with 57.8% for the first quarter of 2007. Gross margin improvements were the result of lower product costs and increased contribution of new products. The prior record gross margin was 58.2% in the fourth quarter of 2007.

"Our strong first quarter revenue growth and milestone achievement of gross profit exceeding 60% for the first time demonstrates continued progress towards our twin goals of attaining positive cash flow and profitability," said Michael Dale, Chairman, President and Chief Executive Officer. "While sales of our existing mechanical heart valve and cryoablation products have been strong, we are very excited about the outlook for incremental future revenues from our most recent introductions as well as products in the pipeline. In particular, we believe our new CryoMaze products and supporting clinical plans have the potential to expand less invasive treatments of atrial fibrillation with excellent outcomes."

Recent and Upcoming New Product Highlights

Surgical Arrhythmias

-- Minimally invasive surgical ablation: The Company is co-sponsoring a

symposium titled "Frontiers in Cryoablation" with Intuitive Surgical

(Nasdaq: ISRG) at the American Association of Thoracic Surgeons meeting

in San Diego, California on Sunday, May 11. The symposium will include

a panel of world renowned cardiac and thoracic surgeons to discuss both

robotic and non-robotic approaches to treating atrial fibrillation on a

minimally invasive basis.

-- ATS CryoMaze surgical ablation system: Several new products are under

development to enhance the utility of the Company's existing products

and tools for the treatment of cardiac arrhythmias. The Company

anticipates launching a next generation ablation clamp with probe in

mid 2008.

Tissue Heart Valves

-- ATS 3f(R) Aortic Bioprosthesis: The Company's first generation tissue

valve has been launched on a targeted basis in France, Scandinavia and

Canada during early 2008.

As announced previously, the Food and Drug Administration (FDA) has

asked ATS to provide additional information and clarification in

support of its PMA for the ATS 3f Aortic Bioprosthesis. The Company

submitted answers to the FDA in March 2008. Management continues to

expect that the ATS 3f Aortic Bioprosthesis will be approved in the

second half of 2008.

-- ATS 3f Enable(TM) Aortic Bioprosthesis: Enrollment continues to

progress with excellent clinical results in the Company's European

clinical trial of its Enable sutureless tissue valve designed to

provide a less invasive approach for aortic valve replacement. The

Company recently implanted the 50th patient in this pivotal trial and

expects to reach enrollment of 100 patients around mid year. The first

regulatory approval for commercialization is expected in mid 2009.

Mechanical Valves

-- ATS Open Pivot AP360(TM) Mechanical Heart Valve: The Company commenced

a limited launch of its ATS AP360 Heart Valve in the first quarter.

The AP360 is the Company's most competitive Open Pivot product, with

the same hemodynamic features as its existing supra annular AP valve

but with a revised cuff design to enable easier suturing. Initial

physician response has been excellent and the company expects to see

measurable revenue growth from this new offering in the second quarter.

Repair Products

-- ATS Simulus(R) Semi-Rigid and Adjustable Flexible Rings: Initial launch

and implants have been completed; surgeon feedback has been very

positive and contributed to revenue growth of 28.0% in the first

quarter of 2008 compared to Q4 2007 and 70.4% compared to the first

quarter of 2007. The ATS Simulus Flexible rings and bands are fast

becoming the annuloplasty device of choice among surgeons performing

surgical robotic mitral valve repair because of the ease of suture


"Our first quarter performance was especially strong with most of the upside coming from our existing products," continued Mr. Dale. "We began the launch of our new products, specifically the 3f Aortic Bioprosthesis and the Open Pivot AP360 Mechanical Heart Valve, towards the end of the quarter so we've yet to see an appreciable revenue impact from these introductions. We expect meaningful revenue from these products to begin in the second quarter and grow sequentially throughout the year. We are confident that the combination of robust growth from existing products and increasing contribution from new products will result in another landmark year for ATS. Furthermore, as top line growth continues, we fully expect the increased leverage will enable enhanced financial performance."

Additional Financial Results

The operating loss for the first quarter of 2008 was $3.6 million compared with an operating loss of $4.4 million in the first quarter of 2007. The net loss for the first quarter of 2008 was $2.4 million, or $0.04 per share, compared with $4.8 million, or $0.11 per share in the first quarter of 2007.

Revised 2008 Revenue Outlook

For the full year 2008 the Company now expects revenue to be in a range of $62 to $66 million versus its previous guidance of $60 to $64 million.

Conference Call Today

ATS management will host a conference call today, May 5, 2008 at 5:00 p.m. ET to discuss its first quarter financial results and current corporate developments. The dial-in number for the conference call is 800-218-4007 for domestic participants and 303-262-2142 for international participants. A live webcast of the call can also be accessed at by clicking on the Investors icon.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 800-405-2236 for domestic participants and 303-590-3000 for international callers, using the passcode 11112192#.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.

ATS Medical, Inc.

Condensed Consolidated Statements of Operations

(in thousands except per share amounts)

Quarter Ended

March 29, March 31,

2008 2007

Net sales $14,845 $10,796

Cost of goods sold 5,897 4,553

Gross profit 8,948 6,243

Operating expenses:

Sales and marketing 6,487 5,923

Research and development 2,206 1,657

General and administrative 3,004 2,616

Amortization of intangibles 891 415

Total operating expenses 12,588 10,611

Operating loss (3,640) (4,368)

Interest expense, net (619) (445)

Other income (expense) 1,918 (6)

Net loss before income taxes (2,341) (4,819)

Income tax expense (70) (1)

Net loss ($2,411) ($4,820)

Net loss per share:

Basic and diluted ($0.04) ($0.11)

Weighted average number of shares outstanding:

Basic and diluted 59,739 42,052

ATS Medical, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

March 29, December 31,

2008 2007


Cash and short-term investments $11,926 $14,669

Accounts receivable 11,488 11,186

Inventories 19,266 18,743

Prepaid expenses 1,016 1,143

Total current assets 43,696 45,741

Property and equipment, net 7,646 7,739

Intangible assets 49,888 50,779

Other assets 1,530 1,638

Total assets $102,760 $105,897

Liabilities & shareholders' equity

Accounts payable $4,959 $4,794

Accrued compensation 2,195 2,361

Other accrued liabilities 2,092 2,000

Current maturities of bank notes payable 2,646 2,457

Warrant liability 2,393 3,913

Total current liabilities 14,285 15,525

Convertible senior notes payable 17,456 17,436

Bank notes payable 5,954 6,143

Payable to CryoCath Technologies Inc. 1,782 1,742

Deferred income taxes 143 95

Shareholders' equity 63,140 64,956

Total liabilities & shareholders' equity $102,760 $105,897

ATS Medical, Inc.

Consolidated Condensed Statements of Cash Flow

(in thousands)

Quarter Ended

March 29, March 31,

2008 2007

Operating activities

Net loss ($2,411) ($4,820)

Adjustments to reconcile net loss to

net cash used in operating activities:

Depreciation and amortization 1,496 904

Stock compensation expense 327 316

Deferred income taxes 48 -

Non-cash interest expense 155 112

Change in value of common stock

appreciation rights and convertible

senior notes derivative liabilities (1,535) (19)

Changes in operating assets and liabilities (576) (1,279)

Net cash used in operating activities (2,496) (4,786)

Investing activities

Maturities (purchases) of short-term

investments, net 2,481 2,567

Payments for technology licenses and

other intangibles - (23)

Purchases of furniture, machinery and

equipment (488) (90)

Net cash provided by investing activities 1,993 2,454

Financing activities

Repayments on notes payable - (283)

Net proceeds from sales of common stock

and warrants 51 15,464

Other 29 76

Net cash provided by financing activities 80 15,257

Other items 161 (52)

Increase (decrease) in cash and

cash equivalents ($262) $12,873

ATS Medical, Inc.

Selected Revenue Information

(in thousands)

Revenue for the Quarter Ended

March 29, March 31,

2008 2007

Heart valve therapy $10,681 $8,992

Surgical arrhythmias 3,848 1,477

Surgical tools & accessories 316 327

Total revenue $14,845 $10,796

SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
2. BioMS Medical announces conference call and web cast for Annual General Meeting
3. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
4. National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients
5. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
6. Engineers harness cell phone technology for use in medical imaging
7. Researchers develop method for transmitting medical images via cell phones
8. ATS Medical Announces First Quarter 2008 Earnings Release Date and Conference Call
9. Inverness Medical Innovations to Participate at Morgan Stanley Global Healthcare Unplugged Conference on April 30, 2008
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. FDA Clears First Medical Product Made From Yulex(R) Natural Rubber
Post Your Comments:
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... ( ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at . 2016 Year ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):